HK1208457A1 - Polymorph forms - Google Patents
Polymorph formsInfo
- Publication number
- HK1208457A1 HK1208457A1 HK15109195.7A HK15109195A HK1208457A1 HK 1208457 A1 HK1208457 A1 HK 1208457A1 HK 15109195 A HK15109195 A HK 15109195A HK 1208457 A1 HK1208457 A1 HK 1208457A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- polymorph forms
- polymorph
- forms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261729174P | 2012-11-21 | 2012-11-21 | |
PCT/JP2013/006853 WO2014080633A1 (en) | 2012-11-21 | 2013-11-21 | Polymorph forms |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1208457A1 true HK1208457A1 (en) | 2016-03-04 |
Family
ID=50775828
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15109195.7A HK1208457A1 (en) | 2012-11-21 | 2015-09-18 | Polymorph forms |
HK15109889.8A HK1209122A1 (en) | 2012-11-21 | 2015-10-09 | Polymorph forms |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15109889.8A HK1209122A1 (en) | 2012-11-21 | 2015-10-09 | Polymorph forms |
Country Status (13)
Country | Link |
---|---|
US (1) | US10179779B2 (de) |
EP (1) | EP2922849B1 (de) |
JP (1) | JP5903681B2 (de) |
KR (1) | KR102191822B1 (de) |
CN (2) | CN108658964B (de) |
BR (1) | BR112015011392A2 (de) |
CA (1) | CA2890861C (de) |
ES (1) | ES2637539T3 (de) |
HK (2) | HK1208457A1 (de) |
MX (1) | MX353994B (de) |
RU (1) | RU2659036C2 (de) |
TW (1) | TWI610929B (de) |
WO (1) | WO2014080633A1 (de) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX355697B (es) * | 2010-04-12 | 2018-04-27 | Supernus Pharmaceuticals Inc | Métodos para producir sales de viloxazina y polimorfos novedosos de las mismas. |
TW201613927A (en) | 2014-09-01 | 2016-04-16 | Bayer Pharma AG | Method for preparation of substituted imidazopyridazines |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
US5750542A (en) | 1993-09-28 | 1998-05-12 | Pfizer | Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors |
DE69232907T2 (de) | 1991-03-28 | 2003-05-15 | Eisai Co Ltd | Neue heterocyclische/cyclische amine |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
JP4970290B2 (ja) * | 2005-02-25 | 2012-07-04 | ファイザー株式会社 | ベンズイソキサゾール誘導体 |
IN2012DN06631A (de) * | 2010-02-16 | 2015-10-23 | Pfizer | |
US8953631B2 (en) | 2010-06-30 | 2015-02-10 | Intel Corporation | Interruption, at least in part, of frame transmission |
BR112013029319A2 (pt) * | 2011-05-18 | 2017-01-31 | Raqualia Pharma Inc | forma polimorfa i de ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2-benzisoxazol-3-il]oxi}metil)piperidina-1-il]metil}-tetrahidro-2h-pirano-4 carboxílico, forma polimorfa ii de ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2-benzisoxazol-3-il]oxi}metil)piperidina-1-il]metil}-tetrahidro-2h-pirano-4 carboxílico, uso e processo, e método para tratar condições de doença mediadas por atividade receptora de 5-ht4 |
-
2013
- 2013-11-21 CA CA2890861A patent/CA2890861C/en active Active
- 2013-11-21 RU RU2015123687A patent/RU2659036C2/ru active
- 2013-11-21 EP EP13856306.9A patent/EP2922849B1/de active Active
- 2013-11-21 KR KR1020157014014A patent/KR102191822B1/ko active IP Right Grant
- 2013-11-21 BR BR112015011392A patent/BR112015011392A2/pt not_active IP Right Cessation
- 2013-11-21 CN CN201810666169.9A patent/CN108658964B/zh active Active
- 2013-11-21 ES ES13856306.9T patent/ES2637539T3/es active Active
- 2013-11-21 CN CN201380058522.0A patent/CN104837836B/zh active Active
- 2013-11-21 TW TW102142568A patent/TWI610929B/zh active
- 2013-11-21 MX MX2015006270A patent/MX353994B/es active IP Right Grant
- 2013-11-21 US US14/442,860 patent/US10179779B2/en active Active
- 2013-11-21 JP JP2015523320A patent/JP5903681B2/ja active Active
- 2013-11-21 WO PCT/JP2013/006853 patent/WO2014080633A1/en active Application Filing
-
2015
- 2015-09-18 HK HK15109195.7A patent/HK1208457A1/xx unknown
- 2015-10-09 HK HK15109889.8A patent/HK1209122A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
US20150322055A1 (en) | 2015-11-12 |
US10179779B2 (en) | 2019-01-15 |
WO2014080633A1 (en) | 2014-05-30 |
CN108658964B (zh) | 2021-07-02 |
CA2890861A1 (en) | 2014-05-30 |
JP2015536903A (ja) | 2015-12-24 |
EP2922849B1 (de) | 2017-07-12 |
CN104837836B (zh) | 2018-07-03 |
MX2015006270A (es) | 2015-08-07 |
RU2015123687A (ru) | 2017-01-10 |
TW201439088A (zh) | 2014-10-16 |
HK1209122A1 (en) | 2016-03-24 |
JP5903681B2 (ja) | 2016-04-13 |
MX353994B (es) | 2018-02-07 |
ES2637539T3 (es) | 2017-10-13 |
KR102191822B1 (ko) | 2020-12-16 |
EP2922849A4 (de) | 2016-03-30 |
BR112015011392A2 (pt) | 2017-07-11 |
RU2659036C2 (ru) | 2018-06-27 |
CN104837836A (zh) | 2015-08-12 |
TWI610929B (zh) | 2018-01-11 |
CN108658964A (zh) | 2018-10-16 |
EP2922849A1 (de) | 2015-09-30 |
KR20150085515A (ko) | 2015-07-23 |
CA2890861C (en) | 2021-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20181889T1 (hr) | Spojevi tetrahidropirazolopirimidina | |
HK1245780B (zh) | 咪唑並吡咯烷酮化合物 | |
IL237341A0 (en) | Compounds that promote neurogenesis | |
GB201209138D0 (en) | Compounds | |
GB201214750D0 (en) | Compounds | |
GB201215357D0 (en) | Compounds | |
EP2887803A4 (de) | Pro-neurogene verbindungen | |
HK1206726A1 (en) | Imidazotriazinone compounds | |
GB201204985D0 (en) | Compounds | |
GB201204125D0 (en) | Compounds | |
HK1211283A1 (en) | Compounds | |
GB201209096D0 (en) | Compounds | |
HK1206356A1 (en) | Lpar - substituted cyanopyrazole compounds lpar- | |
GB201202393D0 (en) | Polymorphs | |
GB201219820D0 (en) | Compounds | |
GB201217310D0 (en) | Compounds | |
HK1209122A1 (en) | Polymorph forms | |
HK1210179A1 (en) | Polymorph | |
GB201203900D0 (en) | Polymorphic form | |
GB201203906D0 (en) | Polymorphic Form | |
GB201203914D0 (en) | Polymorphic form | |
GB201223429D0 (en) | Compounds | |
GB201220029D0 (en) | Compounds | |
GB201219819D0 (en) | Compounds | |
GB201218799D0 (en) | Compounds |